Ionis Q1 revenue up 10% to $132M; TRYNGOLZA brings $6M, guidance raised >20%

IONIS PHARMACEUTICALS INC

2025-Q1 EPS reported -$0.93 revenue$131,612,000

Revenue $132M (+10% YoY); TRYNGOLZA product sales $6M; royalty revenue $64M (SPINRAZA $48M, WAINUA $9M).
GAAP operating loss $146M (non-GAAP $117M); FY2025 revenue guidance raised to $725-750M from >$600M.
Donidalorsen PDUFA Aug 21, 2025; olezarsen Phase 3 sHTG data Q3 2025; ION582 Phase 3 Angelman Q2 2025.
Sapablursen licensed to Ono for $280M upfront; potential $660M milestones plus mid-teen royalties.
Cash & investments $2.1B at Mar 31; expected ~$1.9B year-end after $280M Q2 inflow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.